Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Operating Leases (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Operating Leases data on record, last reported at $35.9 million in Q3 2025.

  • For Q3 2025, Operating Leases fell 10.3% year-over-year to $35.9 million; the TTM value through Sep 2025 reached $35.9 million, down 10.3%, while the annual FY2024 figure was $39.0 million, 9.04% down from the prior year.
  • Operating Leases reached $35.9 million in Q3 2025 per GLUE's latest filing, down from $37.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $44.4 million in Q2 2023 and bottomed at $35.9 million in Q3 2025.
  • Average Operating Leases over 3 years is $40.6 million, with a median of $40.9 million recorded in 2024.
  • Peak YoY movement for Operating Leases: decreased 3.32% in 2024, then dropped 10.3% in 2025.
  • A 3-year view of Operating Leases shows it stood at $42.9 million in 2023, then decreased by 9.04% to $39.0 million in 2024, then dropped by 7.88% to $35.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $35.9 million in Q3 2025, $37.0 million in Q2 2025, and $38.0 million in Q1 2025.